Literature DB >> 1558437

Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution.

P T Onundarson1, J M Rowe, J M Heal, C W Francis.   

Abstract

BACKGROUND: This study was designed to assess the response of patients with thrombotic thrombocytopenic purpura to plasma exchange and to evaluate the role of splenectomy after relapse.
METHODS: The records of all patients with thrombotic thrombocytopenic purpura who had plasma exchange as primary treatment at a single center during a 10-year period were retrospectively reviewed. Response to the initial course of plasma exchange was determined, and the clinical outcome was evaluated in patients whose conditions were either refractory to exchange, responded without relapse, or relapsed after initial response. The outcome of patients treated during relapse with splenectomy was evaluated. A literature review was conducted to determine the clinical outcome in patients treated similarly.
RESULTS: Twenty-seven patients for whom data could be evaluated had been treated in the 10-year period. Twenty-one (78%) responded to the plasma exchange, but the conditions of six (22%) were refractory and these patients died. Eight patients (30%) had one or multiple relapses after initial response but had prolonged remissions after additional plasma exchange alone (two patients) or splenectomy (six patients). A review of 19 reports, including 224 patients with thrombotic thrombocytopenic purpura initially treated with plasma exchange, revealed similar findings, with initial response in 81%, refractoriness in 19%, and relapse after initial response in 27% of patients.
CONCLUSION: Response to plasma exchange in thrombotic thrombocytopenic purpura is associated with an excellent prognosis, and most deaths occur in patients whose conditions are refractory. Relapses after initial response are frequent but can be managed successfully with additional plasma exchange or with splenectomy, which often induces long-term remissions.

Entities:  

Mesh:

Year:  1992        PMID: 1558437

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  11 in total

Review 1.  Case series: splenectomy: does it still play a role in the management of thrombotic thrombocytopenic purpura?

Authors:  Luc Dubois; Daryl K Gray
Journal:  Can J Surg       Date:  2010-10       Impact factor: 2.089

Review 2.  Thrombotic thrombocytopenic purpura: recognition and management.

Authors:  Joseph E Kiss
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

Review 3.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

Review 4.  The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura.

Authors:  G A Veltman; A Brand; O C Leeksma; G J ten Bosch; J H van Krieken; E Briët
Journal:  Ann Hematol       Date:  1995-05       Impact factor: 3.673

5.  Successful treatment of recurrent thrombotic thrombocytopenic purpura with plasmapheresis and vincristine.

Authors:  S Van Gool; P Brock; P Van Laer; R Van Damme-Lombaerts; W Proesmans; M Casteels-Van Daele
Journal:  Eur J Pediatr       Date:  1994-07       Impact factor: 3.183

Review 6.  The thrombocytopenic purpuras. Recognition and management.

Authors:  S Gillis
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

7.  Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange.

Authors:  A Pereira; R Mazzara; J Monteagudo; C Sanz; L Puig; A Martínez; A Ordinas; R Castillo
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

Review 8.  Treatment of adult-onset Still's disease: a review.

Authors:  Yvan Jamilloux; Mathieu Gerfaud-Valentin; Thomas Henry; Pascal Sève
Journal:  Ther Clin Risk Manag       Date:  2014-12-22       Impact factor: 2.423

9.  Severe primary refractory thrombotic thrombocytopenic purpura (TTP) in the post plasma exchange (PEX) and rituximab era.

Authors:  Sowmya Goranta; Smit S Deliwala; Tarek Haykal; Ghassan Bachuwa
Journal:  BMJ Case Rep       Date:  2020-06-11

Review 10.  Life-threatening complications of adult-onset Still's disease.

Authors:  Petros Efthimiou; Sabeeda Kadavath; Bella Mehta
Journal:  Clin Rheumatol       Date:  2014-01-17       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.